Nanomedicine News

RSS

Nanomaterials Highlighted as Key Player in Atherosclerosis Therapeutics

Nanomaterials Highlighted as Key Player in Atherosclerosis Therapeutics

Authors conducted a systematic review of current trends in nanomaterials-based therapeutic strategies against atherosclerosis.

12 Apr 2022

Cisplatin-Based Nanomedicines may Potentially Revolutionize Oncological Treatment

Cisplatin-Based Nanomedicines may Potentially Revolutionize Oncological Treatment

Innovation Center of Nanomedicine (Center Director: Prof. Kazunori Kataoka) announced that a reviw article for nanomedicines in cisplatin-based cancer therapy was accepted by Journal of Controlled Release and published online on March 31, 2022: Y. Han, P. Wen, J. Li and K. Kataoka, J. Controlled Release, 2022, 345, 709-720.

12 Apr 2022

Nanomedicine for Treating Deadly Brain Cancers

Nanomedicine for Treating Deadly Brain Cancers

Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka) has announced that Dr. Sabina Quader et al. published a review article focusing on the recent nanomedicines for brain cancers on Advanced Drug Delivery Review in this March. CNS tumors remain among the deadliest forms of cancer, resisting conventional and new treatment approaches, with mortality rates staying practically unchanged over the past 30 years.

11 Apr 2022

Synthesizing Anticancer Nanomedicine Systems from Green Sources

Synthesizing Anticancer Nanomedicine Systems from Green Sources

The importance of developing plant-based nanoparticles that can be explored to develop novel anticancer chemotherapeutic has been highlighted in new research.

8 Apr 2022

New Antiglaucoma Nano-Based Drug Carrier Proposed

New Antiglaucoma Nano-Based Drug Carrier Proposed

A novel chitosan -graphene quantum dots (CS-GQDs) nanocomposite for the administration of latanoprost (LP), an antiglaucoma medication has been created.

6 Apr 2022

Scientists Identify Two Subsets of Neutrophils, Likely to Help in Treatments that Address Inflammatory Diseases

Scientists Identify Two Subsets of Neutrophils, Likely to Help in Treatments that Address Inflammatory Diseases

Researchers at the University of Illinois Chicago recognized two subtypes of neutrophils using a protein nanoparticle they designed and discovered that one of the subtypes can be employed as a drug target for inflammatory diseases.

6 Apr 2022

Nanodrug Technology Simultaneously Delivers Two Therapies to Attack Malignancy with Precision

Nanodrug Technology Simultaneously Delivers Two Therapies to Attack Malignancy with Precision

Tel Aviv University researchers have developed a nanodrug technology that instantaneously delivers two therapies to target malignancy with accuracy, to resolve the resistance of certain cancers to various types of treatments.

5 Apr 2022

Nanofiber-Hydrogel Treatment for Spinal Cord Injury

Nanofiber-Hydrogel Treatment for Spinal Cord Injury

Novel research on nervous tissue repair has emerged from the journal, Cells, through the use of mesenchymal stromal cells and a nanofiber hydrogel composite.

4 Apr 2022

Nanomedicine, a Promising Tool in Diabetic Kidney Disease Therapeutics

Nanomedicine, a Promising Tool in Diabetic Kidney Disease Therapeutics

Researchers outline the potential of using nanomaterials for the diagnosis and treatment of diabetic kidney disease (DKD).

30 Mar 2022

Nanotechnology Supports Stable Delivery of Cannabidiol

Nanotechnology Supports Stable Delivery of Cannabidiol

Using a nano-based approach to drug delivery, researchers demonstrate a stable approach to rectal delivery of cannabidiol.

30 Mar 2022

Previous
1
...
34
35
36
37
38
39
40
...
551
Next

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.